Petra Kaufmann

Petra Kaufmann

Company: Affinia Therapeutics

Job title: Chief Medical Officer


Panel Discussion: Dose Optimization for Neurological Gene Therapies 12:15 pm

Read more

Determining Optimal Dose & Considering Disease Progression for Time of Intervention 11:35 am

Determining the dose for first-in-human gene therapy studies Considering the best route of administration Understanding disease progression to optimize the timing of interventionRead more

day: Day One: Track B AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.